Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00219)
Name
Droxidopa
Synonyms    Click to Show/Hide the Synonyms of This API
droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; 3916-18-5; threo-Dopaserine; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; UNII-J7A92W69L7; SM 5688; CHEBI:31524; L-dihydroxyphenylserine; Droxidopa (L-DOPS); L-threo-dihydroxyphenylserine; J7A92W69L7; DL-threo-DOPS; DL-threo-beta-(3,4-Dihydroxyphenyl)serine; L-Tyrosine, beta,3-dihydroxy-, (betaR)-; Droxydopa; L-threo-3,4-dihydroxyphenylserine; Norethra; (2RS,3RS)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-3-HYDROXY-PROPIONIC ACID; Droxidopa [Latin]; DL-threo-Dihydroxyphenylserine; threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; 3,4-Dihydroxyphenylserine; BRN 2852792; droxidopum; L-Tyrosine, beta,3-dihydroxy-, threo-; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Droxidopa [USAN:INN:JAN]; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-; Northera (TN); L-threo DOPS; L-threo-DOPS; Dops (TN); L-threo-3-(3,4-Dihydroxyphenyl)serine; threo-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid; (-)-(2S,3R)-2-Amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid; 1-14-00-00685 (Beilstein Handbook Reference); SCHEMBL134299; GTPL7391; Droxidopa (JP17/USAN/INN); CHEMBL2103827; Droxidopa (L-DOPS,SM-5688); DTXSID201017236; BCP06516; ZINC1482049; ANW-57465; BDBM50103611; MFCD00799030; (betaR)-beta,3-dihydroxy-L-tyrosine; L-DOPS, >=98% (HPLC); (2S,3R)-3,4-dihydroxy-phenylserine; AKOS015889899; CCG-222060; DB06262; SM-5688; NCGC00344531-04; AS-61328; HY-13458; (-)-threo-3-(3,4-Dihydroxyphenyl)-L-serine; D01277; Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-; AB01566868_01; DL-Tyrosine, beta,3-dihydroxy-, threo- (9CI); 916A185; Q907853; SR-01000883755; Droxidopa (L-threo-3-(3,4-Dihydroxyphenyl)serine); L-Tyrosine, beta,3-dihydroxy-, (beta-R)- (9CI); Q-201050; SR-01000883755-1; UNII-24A0V01WKS component QXWYKJLNLSIPIN-JGVFFNPUSA-N; 23651-95-8,1260173-94-1(HCl); (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid; (-)-(2S,3R)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic acid; (2RS,3RS)-2-AMINO-3-(3,4-DIhydroxyphenyl)-3-HYDROXY-propanoic acid; (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid / L-threo-3,4-Dihydroxyphenylserine; 1260173-94-1
Clinical Status
Approved
Disease Indication Neurogenic orthostatic hypotension ICD-11: 8D87 [1]
PubChem CID
92974
Formula
C9H11NO5
Canonical SMILES
C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
InChI
1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
InChIKey
QXWYKJLNLSIPIN-JGVFFNPUSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=92974"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 213.19 Topological Polar Surface Area 124
XlogP -3.2 Complexity 235
Heavy Atom Count 15 Rotatable Bond Count 3
Hydrogen Bond Donor Count 5 Hydrogen Bond Acceptor Count 6
Full List of Drug Formulations (DFMs) Containing This API
          Droxidopa 300 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c red no. 40; Fd&c blue no. 1; Fd&c yellow no. 5; Magnesium stearate; Mannitol; Titanium dioxide; Gelatin; Starch, corn
                   Dosage Form Oral Capsule
                   Company Lundbeck Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Allura red AC dye DIG Info Solute carrier SLCO2B1 (Ki = 4.7 uM) [2]
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [3]
Hydrazine yellow DIG Info GABA(A) receptor alpha-1 (IC50 = 13 uM) [2]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [4]
Allura red AC dye DIG Info Solute carrier SLCO2B1 (Ki = 2.59 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
          Droxidopa 100 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Magnesium stearate; Mannitol; Ferric oxide red; Ferrosoferric oxide; Titanium dioxide; Gelatin; Starch, corn
                   Dosage Form Oral Capsule
                   Company Lundbeck Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [2]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [4]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
          Droxidopa 200 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Magnesium stearate; Mannitol; Ferric oxide yellow; Ferrosoferric oxide; Titanium dioxide; Gelatin; Starch, corn
                   Dosage Form Oral Capsule
                   Company Lundbeck Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [2]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [4]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
References
1 FDA label for approved droxidopa from the official website of the U.S. Food and Drug Administration.
2 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
4 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
5 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.